Glutamatergic mechanisms in schizophrenia: Current concepts

Current Psychosis and Therapeutics Reports

Volumn 4, Issue 1, 2006, Pages 27-34

  Beneyto, Monica ^a   Kristiansen, Lars V ^b   McCullumsmith, Robert E ^b   Meador Woodruff, James H ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLYCINE; NEUROLEPTIC AGENT;

CLINICAL TRIAL; CYTOLOGY; GENETIC ANALYSIS; HUMAN; META ANALYSIS; NEUROIMAGING; NEUROTRANSMISSION; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW;

EID: 33750349702     PISSN: 15458083     EISSN: 15458091     Source Type: Journal    
DOI: 10.1007/BF02629411     Document Type: Review

References (56)

1. Hertzmann M, Reba RC, Kotlyarov EV: Single photon emission computed tomography in phencyclidine and related drug abuse. Am J Psychiatry 1990, 147:255-256.
2. Mimics K, Lewis DA: Genes and subtypes of schizophrenia. Trends Mol Med 2001, 7:281-283.
3. Martucci L, Wong AH, Trakalo J, et al.: N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case-control analyses. Am J Med Genet B Neuropsychiatr Genet 2003, 119:24-27.
4. Di Maria E, Gulli R, Begni S, et al.: Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study. Am J Med Genet B Neuropsychiatr Genet 2004, 128:27-29.
5. Iwayama-Shigeno Y, Yamada K, Itokawa M, et al.: Extended analyses support the association of a functional (GT) n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci Lett 2005, 378:102-105.
6. Makino C, Fujii Y, Kikuta R, et al.: Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am J Med Genet B Neuropsychiatr Genet 2003, 116:17-22.
7. Shibata H, Joo A, Fujii Y, et al.: Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia. Psychiatr Genet 2001, 11:139-144.
8. Bah J, Quach H, Ebstein RP, et al.: Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. Neuroreport 2004, 15:1987-1991.
9. Chen Q, He G, Wu S, et al.: A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 2005, 73:21-26.
10. Takaki H, Kikuta R, Shibata H, et al.: Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004, 128:6-14.
11. Hong CJ, Liao DL, Shih HL, et al.: Association study of PICK1 rs3952 polymorphism and schizophrenia. Neuroreport 2004, 15:1965-1967.
12. Deng X, Shibata H, Ninomiya H, et al.: Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry 2004, 4:21.
13. Owen MJ, Craddock N, O'Donovan MC: Schizophrenia: genes at last? Trends Genet 2005, 21:518-525. Presents several interesting candidate genes in schizophrenia.
14. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005, 10:40-68. Good review on genetic aspects on schizophrenia and implicated genes.
15. Tunbridge E, Burnet PW, Sodhi MS, et al.: Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse 2004, 51:112-118.
16. Jacquet H, Demily C, Houy E, et al.: Hyperprolinemia is a risk factor for schizoaffective disorder. Mol Psychiatry 2005, 10:479-485.
17. Bender HU, Almashanu S, Steel G, et al.: Functional consequences of PRODH missense mutations. Am J Hum Genet 2005, 76:409-420.
18. Fuchs SA, Berger R, Klomp LW, et al.: D-amino acids in the central nervous system in health and disease. Mol Genet Metab 2005, 85:168-180.
19. Corfas G, Roy K, Buxbaum JD: Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004, 7:575-580. Mechanistic overview of Neuregulin-1 in schizophrenia.
20. Straub RE, Jiang Y, MacLean CJ, et al.: Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002, 71:337-348.
21. Bray NJ, Preece A, Williams NM, et al.: Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005, 14:1947-1954.
22. Fanous AH, van den Oord EJ, Riley BP, et al.: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005, 162:1824-1832.
23. McCullumsmith RE, Clinton SM, Meador-Woodruff JH: Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol 2004, 59:19-45. Review article suggesting that schizophrenia is a disorder of neuroplasticity, associated with molecular abnormalities of the glutamate synapse.
24. Vawter MP, Crook JM, Hyde TM, et al.: Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 2002, 58:11-20.
25. Eastwood SL, McDonald B, Burnet PW, et al.: Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995, 29:211-223.
26. Ibrahim HM, Hogg Jr AJ, Healy DJ, et al.: Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 2000, 157:1811-1823.
27. Scarr E, Beneyto M, Meador-Woodruff JH, et al.: Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 2005, 30:1521-1531.
28. Porter RH, Eastwood SL, Harrison PJ: Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 1997, 751:217-231.
29. Ohnuma T, Augood SJ, Arai H, et al.: Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 1998, 56:207-217.
30. Kerwin R, Patel S, Meldrum B: Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990, 39:25-32.
31. Zavitsanou K, Ward PB, Huang XF: Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 2002, 27:826-833.
32. Meador-Woodruff JH, Clinton SM, Beneyto M, et al.: Molecular abnormalities of the glutamate synapse in the thalamus in schizophrenia. Ann N Y Acad Sci 2003, 1003:75-93.
33. Kristiansen LV, Meador-Woodruff JH: Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005, 78:87-93.
34. Ohnuma T, Kato H, Arai H, et al.: Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 2000, 11:3133-3137.
35. Clinton SM, Haroutunian V, Davis KL, et al.: Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 2003, 160:1100-1109.
36. Mimics K, Middleton FA, Marquez A, et al.: Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
37. Imai C, Sugai T, Iritani S, et al.: A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosci Lett 2001, 305:185-188.
38. Toyooka K, Iritani S, Makifuchi T, et al.: Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 2002, 83:797-806.
39. Bruneau EG, McCullumsmith RE, Haroutunian V, et al.: Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res 2005, 75:27-34.
40. Smith RE, Haroutunian V, Davis KL, et al.: Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport 2001, 12:2885-2887.
41. Smith RE, Haroutunian V, Davis KL, et al.: Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 2001, 158:1393-1399.
42. Steen RG, Hamer RM, Lieberman JA: Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30:1949-1962.
43. Steen RG, Hamer RM, Lieberman JA: Measurement of Brain Metabolites by (1)H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Neuropsychopharmacology 2005.
44. Tebartz van Elst L, Valerius G, Buchert M, et al.: Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005, 58:724-730.
45. Tebartz van Elst L, Valerius G, Buchert M, et al.: Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy Study. Biol Psychiatry 2005.
46. Holcomb HH, Lahti AC, Medoff DR, et al.: Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005, 30:2275-2282.
47. Heresco-Levy U, Javitt DC, Ebstein R, et al.: D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005, 57:577-585. Latest paper investigating NMDA receptor augmentation strategies.
48. Heresco-Levy U, Javitt DC, Ermilov M, et al.: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56:29-36.
49. Tsai G, Lane HY, Yang P, et al.: Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004, 55:452-456.
50. Cascella NG, Macciardi F, Cavallini C, et al.: d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neurol Transm Gen Sect 1994, 95:105-111.
51. Goff DC, Tsai G, Manoach DS, etal.: Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995, 152:1213-1215.
52. Yurgelun-Todd DA, Coyle IT, Gruber SA, et al.: Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res 2005, 138:23-31. Important work combining fMRI with modulation of glutamatergic neurotransmission.
53. Ito K, Hicks TP: Effect of the glycine modulatory site of the N-methyl-D-aspartate receptor on synaptic responses in kitten visual cortex. Neurosci Lett 2001, 303:95-98.
54. Tuominen HJ, Tiihonen J, Wahlbeck K: Glutamatergic drugs for schizophrenia: a systematic review and metaanalysis. Schizophr Res 2005, 72:225-234.
55. Tsai G, Coyle JT: Clutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002, 42:165-179.
56. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001, 158:1367-1377.